GSK Vietnam steps up action against antimicrobial resistance, promoting rational antibiotic use and wider vaccine coverage.

GSK funding has been allocated to new research programmes combining expertise and using cutting edge AI technology to ...

GSK is investing £45m with the Fleming Initiative to launch six research programmes using cutting-edge AI to tackle ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

According to GSK, the programme of 'Grand Challenge' research projects will make use of AI and other cutting-edge ...

GSK’s leadership in respiratory medicine goes beyond science—uniting research, collaboration, and care to transform outcomes ...

The FTSE 100 opened lower on Friday, falling 1% to 9432.38, as global markets struggled to absorb a surge in volatility ...

Just a few weeks after the company announced licensing agreements with Empirico and Syndivia, GSK announced a strategic ...

By Kamal Choudhury (Reuters) -Shares of AnaptysBio fell more than 5% on Friday after the U.S. drug developer and GSK's oncology unit, Tesaro, filed lawsuits against each other, with both claiming a ...

Drug resistance — known as antimicrobial resistance, or AMR — emerges when pathogens mutate in ways that make treatments ...

GSK & LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology: London, UK Thursday, November 20, 2025, 09:00 Hrs [IST] GSK plc and LTZ Therapeutics ...

GSK and the Fleming Initiative have announced six new research programmes to combat antimicrobial resistance (AMR), backed by ...